Arkolith/Insider Trading/KIN/Form 4

Lien Lyndon

DirectorKindred Biosciences, Inc. (KIN) · full profile →Form 4 · filed Aug 30, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 27, 2021Disposed to issuer(D)47K$4.17$196K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001250853-21-000084) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML